![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.075 | 16.67% | 0.525 | 0.50 | 0.55 | 0.525 | 0.45 | 0.45 | 4,522,734 | 16:04:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 2k | -1.27M | -0.0047 | -1.11 | 1.21M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/1/2024 08:00 | Preclinical studies!! Need I say more…. | ![]() nobbygnome | |
11/1/2024 11:33 | To add to my previous posting, a couple of further observations regarding Nanogenics/Nuvec. Firstly people say that N4 only has one product and that it is years away from monitisation. This is only partially true because the investment in Nanogenics gives them both a product that is near to clinic,which even in its non refined state is better than anything on the market that addresses a clear and growing need, together with a string of other promising products. To quote from the Nanogenics website "Our lead product, ECP-105, is our novel glaucoma therapy. We expect to have it in clinic in 2025, followed closely by several other promising medicines." The Nanogenics investment therefore gives them plenty of options. The other comment I would make is that Nuvec being a delivery system means that it has in the past been beholden to the drug developers to get Nuvec into clinic. The company have spoken before about bringing their own products to market and what the Nanogenics investment does is bring a drug developer together with a delivery system meaning that N4 are no longer beholden to third party drug developer timescales, indeed N4 have already stated that the next stage of Nuvecs development is to identify a clear product to take into clinic. Nuvec could be used for Nanogenics drug development or Nanogenics could develop drugs for Nuvec. Either way it speeds up the timelines to get into clinic. | ![]() fydo | |
08/1/2024 15:12 | Hmmmm Fydo’s first post since October 2019 and as far as I can see he has never posted on N4P before. Who has tipped him the wink…. | ![]() nobbygnome | |
08/1/2024 11:26 | Things are coming together here and the dots are being joined. One of the issues being discussed is funding. N4 have already stated that Nanogenics could be funded by third parties. To this end it is interesting that Dr Simon Newman the Chief Scientific officer of Nanogenics will take up the same role at the Brain Tumour Charity next month whilst continuing that role at Nanogenics. Interesting because the Brain Tumour Charity is both heavily involved in tumour research itself but more importantly is a major financier of tumour research both directly and through third parties. To have the Nanogenics CSO acting in the interests of Nanogenics/Nuvec could be very advantageous. | ![]() fydo | |
08/1/2024 07:35 | Insider trading?!? Hmmmm… I thought it was funny that they referenced immunogenicity problems with the viral vector. They haven’t put the Nuvec particles into humans yet so have no idea if there will be any tolerability issues with their own product! This project remains many years from monetisation…. | ![]() nobbygnome | |
08/1/2024 07:29 | Explains the £55k late reported buy on Friday with the RNS this morning. | ![]() mo7800 | |
07/1/2024 15:08 | Well hope they continue to go up tomorrow. | ![]() pwal | |
07/1/2024 14:38 | They had a few other ideas, re-engineering Viagra etc that failed, now a slow slog to prove what they are left with (nuvec) works. | ![]() tp6 | |
05/1/2024 11:14 | Because they've got 1 early stage product, no revenue and no money | ![]() dplewis1 | |
05/1/2024 10:04 | I bought into this as a punt at 0.77p. I have done some research into this and it's got an awful lot of upside to it. Why did it drop from 12p all the way down? | ![]() mo7800 | |
19/12/2023 08:17 | Yeah but it's 20 years now they have been flogging that horse or land in Greece so you cannot say one stock is lifestyle and another is not when most are when it comes to this game. And yes the future is not the past | ![]() dave4545 | |
19/12/2023 08:14 | No it isn’t as the directors have largely been paying themselves in shares. The issues there are caused by the delightful Foundation… | ![]() nobbygnome | |
18/12/2023 22:21 | So Minoan is not a lifestyle stock then Nobby ? :-)) They're all lifestyle stocks, the key is to be in them at the right time before they spike a few times a year. | ![]() dave4545 | |
18/12/2023 21:43 | As a long term investor here after a fall from 5p to 0.7 in 2 years, you then celebrate a rise to 1.1. It’s still down the best part of 80%. Hmmmm…. | ![]() nobbygnome | |
18/12/2023 21:20 | A long downtrend with a 40% burst. Good one. | ![]() featherby81 | |
18/12/2023 21:16 | The chart above looks like one long downtrend to me…. | ![]() nobbygnome | |
18/12/2023 20:58 | You still trolling chat boards you ain’t invested in and missing out on gains I see Nobby! #Winner | ![]() featherby81 | |
18/12/2023 20:31 | Another nothing announcement; this technology is sooooooooo far from being commercialised. A triumph of hope over expectation…. | ![]() nobbygnome | |
18/12/2023 17:59 | Profit taken & money moving to APH | blackhorse23 | |
18/12/2023 14:45 | I agree Dave. News has not been reflected in the current rise yet but it feels like its about to pop into close. Enjoy the week. | genierub | |
18/12/2023 12:17 | Definitely looking better though - If seller has departed this is 1p+ - | ![]() tomboyb | |
18/12/2023 12:13 | My break even is 4p. Not sure it will get to that anytime soon. But hope is there. | ![]() pwal |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions